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Treatment of relapse after related HLA-haploidentical T cellereplete bone marrow transplantation (hap-
loBMT) with post-transplantation cyclophosphamide (PTCy) using haploidentical donor lymphocyte infusion
(haploDLI) is not documented. All patients who received haploDLI after haploBMT with PTCy between June
2003 and October 2012 were identiﬁed and assessed for graft-versus-host disease (GVHD) and outcomes.
Forty patients received 52 haploDLI doses. Sixteen patients had acute myeloid leukemia, 11 had lymphomas,
and 34 had nonmyeloablative conditioning before haploBMT. The median time from haploBMT to relapse was
183 (range, 0 to 1399) days. The median age at haploDLI was 48 (range, 3 to 70) years. The ﬁrst haploDLI doses
were 1  105 CD3þ cells/kg with subsequent escalation. The most commonly used ﬁrst haploDLI dose was
1  106 CD3þ cells/kg. The median follow-up after haploDLI was 7 (mean, 15.4; range, .5 to 96) months for the
entire cohort, and 17.5 (mean, 28; range, 2.4 to 96) months for the responders. Acute GVHD developed in
10 patients (25%), 6 patients had grade 3 to 4, and 3 developed chronic GVHD. Twelve (30%) patients achieved
a complete response (CR) with a median duration of 11.8 (mean, 22.5; range, .4 to 94) months. At last follow-
up, 8 responders were alive in CR; 6 for over a year. HaploDLI for relapse after haploBMT is associated with
acceptable toxicities and can result in durable responses.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION METHODS AND MATERIALS
Donor lymphocyte infusion (DLI) is an established
therapeutic option for relapsed disease after HLA-matched
sibling or unrelated donor allogeneic blood or marrow
transplantation, but it is associated with signiﬁcant risk of
graft-versus-host-disease (GVHD) and only a modest
antitumor activity [1-8]. Several factors affect the likeli-
hood of responding to DLI, the most important of which
are the underlying disease and extent of relapse at time of
DLI [1].
Promising results have been reported with related HLA-
haploidentical T cellereplete bone marrow transplantation
(haploBMT) with post-transplantation high-dose cyclo-
phosphamide (PTCy) [9-11]. As with other types of bone
marrow transplantation (BMT), relapse after haploBMT
continues to be a major problem [12-15]. There are limited
published data on DLI use after haploBMT [16-18] and none
after haploBMT with PTCy. We undertook a dose-escalation
approach to evaluate the optimal dosing of DLI for relapsed
disease after haploBMT with PTCy. Here, we report a retro-
spective analysis of our cohort of all patients who received
DLI collected from HLA-haploidentical donors (haploDLI) for
relapsed disease after haploBMT.edgments on page 318.
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After approval by the institutional review board, we retrospectively
identiﬁed all patients who received haploDLI for relapsed hematologic
malignancies after haploBMT with PTCy at Johns Hopkins University be-
tween June 1, 2003 and October 1, 2012. Minimal residual disease (MRD)
relapses were deﬁned by the new detection of ﬂow cytometric or cytoge-
netic evidence of disease after haploBMT or by progressive loss of donor
chimerism (LOC) thought to represent recurrence, in the absence of overt
evidence of hematologic relapse. All patients were included and there were
no exclusion criteria based on age, gender, disease type, conditioning
regimen, or any other feature.
Administration of HaploDLI
After obtaining donor’s consent, haploDLI were collected by apheresis
according to standard protocol at Johns Hopkins University. The CD3þ cell
count was determined by ﬂow cytometry and was used for calculating the
haploDLI dose. All patients who received haploDLI were off immunosup-
pressive agents and without evidence of active GVHD at time of adminis-
tration. We had estimated that the haploDLI dose that can be administered
initially without an unacceptable incidence of severe GVHD should be at
least 100-fold lower, or approximately 1  105 to 1  106 CD3þ T cells/kg,
than the dose typically used in HLA-identical DLI (1 107 to 1 108 CD3þ T
cells/kg) [19,20]. Therefore, the haploDLI administration was performed in a
dose-escalation manner starting with 1  105 CD3þ T cells/kg of recipient’s
ideal body weight.
Response Criteria and GVHD Evaluation
Hematologic relapses and responses were deﬁned using standard
disease-speciﬁc criteria [1]. A complete remission (CR) after haploDLI
administration required disappearance of all MRD (ie, respective ﬂow
cytometric or cytogenetic abnormality in bone marrow [BM]). All patients
underwent BM examination on day 60 after haploDLI to assess for response,
or sooner if clinically indicated. Patients with lymphoma underwent
radiologic imaging as well. The Keystone staging system was used to score
acute GVHD (aGVHD) [21] and the Seattle criteria were used for chronic
GVHD 9 (cGVHD) [22].Transplantation.
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Relapses, responses, and GVHD scores were assessed by 2 authors
independently (A.M.Z. and P.F.) and then veriﬁed by a third investigator
(J.B.M.). The electronic medical record was used to collect demographic,
clinical, and laboratory data. Characteristics of the haploDLI, including
number of infusions and cell doses, were collected from the Cell Therapy
Laboratory and electronic medical record. Patients were followed until
death or December 1, 2012, whichever was ﬁrst. Duration of response was
calculated from the date of ﬁrst documentation of response. Overall survival
was calculated from date of administration of last haploDLI. Based on the
heterogeneity of the patient population in terms of underlying disease,
burden at relapse, difference in patients’ clinical conditions, the relatively
small sample size, the use of various doses of haploDLI, descriptive rather
than inferential statistics were used to analyze data.Table 2
Characteristics of Haploidentical Donor Lymphocyte Infusions (haploDLI)
HaploDLI Characteristic Number (HaploDLI, n ¼ 52
Doses; Patients, n ¼ 40)
Cytoreductive chemotherapy orRESULTS
Demographics and Baseline Characteristics
The demographics and baseline characteristics of 40 pa-
tients who have received haploDLI are shown Table 1. All
patients had received PTCy, tacrolimus, and mycophenolate
mofetil for GVHD prophylaxis after haploBMT. In total, 14
patients developed GVHD after the haploBMT (2 had grade
2 GVHD and 2 had grade 3 GVHD), with resolution in all 4
before haploDLI. The median time from haploBMT to diag-
nosis of relapse was 183 days (7 relapses within 3 months of
BMT, 27 relapses within ﬁrst year, with only 5 relapses after
2 years). Thirty-ﬁve patients received haploDLI for overt
hematologic or radiologic relapse, 4 for MRD relapse detec-
ted by ﬂow cytometry or cytogenetics, and 1 for progressive
LOC concerning for relapse. The median follow-up for the
entire cohort from time of ﬁrst haploDLI administration wasTable 1
Demographics and Baseline Characteristics of 40 patients with Hematologic
Malignancies Who Received HLA-Haploidentical Donor Lymphocyte In-
fusions (haploDLI) for Relapsed Disease after HLA-Haploidentical Bone
Marrow Transplantation (haploBMT)
Characteristic Number (N ¼ 40)
Gender
M 27
F 13
Age at haploDLI (yr)
20 9
21-50 13
51 18
Disease
Acute myeloid leukemia 16
Non-Hodgkin lymphoma 6
Hodgkin lymphoma 5
Multiple myeloma 4
Acute lymphoblastic lymphoma 3
Chronic myeloid leukemia 1
Other* 5
Conditioning regimen
Myeloablative (BU/Cy) 6
Nonmyeloablative (FLU/Cy/TBI) 34
Type of relapse
Hematologic 35
MRD or LOC 5
Time from haploBMT to relapse (mo)
3 7
>3-6 8
>6-12 12
>12-24 8
>24 5
Bu indicates busulfan; Cy, cyclophosphamide; FLU, ﬂudarabine; TBI, total
body irradiation; MRD, minimal residual disease; LOC, loss of donor
chimerism.
* Other diseases included atypical chronic myeloid leukemia (n ¼ 1),
myelodysplastic syndrome (n ¼ 1), plasmacytoid dendritic cell neoplasm
(n ¼ 1), chronic lymphocytic leukemia (n ¼ 1), and T cell prolymphocytic
leukemia (n ¼ 1).7 months (mean, 15.4; range, .5 to 96 months). For the 12
responders, the median follow-up was 17.5 months (mean,
28; range, 2.4 to 96 months).HaploDLI Characteristics
Between August 8, 2003 and September 27, 2012, 52
doses of haploDLI were administered to the 40 patients who
relapsed after haploBMT (Tables 1 and 2). Thirty-two pa-
tients received only 1 haploDLI dose. Chemotherapy (27
patients) or radiotherapy (1 patient) was administered
before administration of 33 haploDLI doses. The patients’
median age at time of ﬁrst haploDLI administration was
48 years (mean, 42; range, 3 to 70 years). The median time
from relapse to ﬁrst haploDLI administration was 56 days
(mean, 119 days; range, 7 to 730 days). The ﬁrst haploDLI
doses used in the ﬁrst 5 patients were 1  105 CD3þ/kg.
Because no clinical responses or GVHD were observed, sub-
sequent patients received higher initial doses, with escala-
tion allowed in absence of GVHD. The majority of patients
(29 patients, 72.5%) received 1  106 CD3þ/kg as their ﬁrst
haploDLI dose, and 8 patients (20%) received escalating dosesradiotherapy before haploDLI
Yes 33 doses (28 patients)
No 19 doses (12 patients)
Total number of haploDLI doses received
1 32
2 5
3 2
4 1
Time from diagnosis of relapse to ﬁrst
haploDLI administration (d)
30 11
31-60 10
61-90 7
91-180 3
181-360 6
361 3
First haploDLI dose (CD3þ cells/kg IBW)
1  105 5
1  106 29
5  106 2
1  107 3
5  107 1
All haploDLI doses (CD3þ cells/kg IBW)
1  105 5
5  105 1
1  106 30
3  106 1
5  106 4
1  107 9
1  108 2
Year in which ﬁrst haploDLI was
administered
2003 1
2004 4
2005 2
2006 1
2007 0
2008 5
2009 3
2010 7
2011 9
2012 8
IBW indicates ideal weight.
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tered after haploDLI.GVHD Post HaploDLI
Out of the 40 patients who received haploDLI, 10 devel-
oped aGVHD (25%). Eight patients had grade 2 to 4 (20%), and
6 had grade 3 to 4 aGVHD (15%). Grade 2 to 4 aGVHD
occurred after 5 of 30 (16.7%) haploDLI doses of 1106 CD3þ/
kg, after 1 of 4 (25%) haploDLI doses of 5  106 CD3þ/kg, and
after 2 of 9 (22.2%) haploDLI doses of 1 107 CD3þ/kg. Grade
3 to 4 aGVHD occurred after a haploDLI dose of 1106 CD3þ/
kg in 3 patients, after 5  106 CD3þ/kg in 1 patient, and after
1  107 CD3þ/kg in 2 patients. Only 1 of the 8 patients who
developed grade 2 to 4 aGVHD received more than 1 dose of
haploDLI; this patient initially received 1  106 CD3þ/kg
without response of GVHD, then developed grade 3 aGVHD
after a second dose of 1  107 CD3þ/kg. Interestingly, no
aGVHD was observed after haploDLI in a 13-year-old patient
who received 2 separate haploDLI doses of 1  108 CD3þ/kg,
both of them given as ﬁnal 2 doses of a 4-dose escalation. Six
of the 8 patients who developed grade 2 to 4 aGVHD had
received chemotherapy or radiation treatment before hap-
loDLI administration. Two patients with severe aGVHD (both
grade 3) died within 6 weeks of haploDLI administration:
both from sepsis. In total, 3 patients developed cGVHD, of
whom 2 had extensive stage, including 1 case of bronchiolitis
obliterans. Both patients who developed extensive cGVHD
remain alive and disease free.Responses and Survival
Of the 40 patients treated, 12 received haploDLI without
any other therapy, and only 1 of those patients achieved a
remission. Of the 28 patients who received cytoreductive
therapy before haploDLI, 11 achieved a CR. Overall, 12 (30%)
patients responded to haploDLI, all achieving a CR, with a
median response duration of 11.8 months (mean,
22.5 months; range, .4 to 94 months) (Table 3). Three of the
4 (75%) patients treated forMRD responded, whereas 9 of the
35 (26%) treated for overt relapse responded. The patient
who received haploDLI for progressive LOC did not respond
and progressed to hematologic relapse. The median age of
responders was 52.5 years (range, 13 to 70 years). Ten re-
sponders received haploDLI within 4 months of relapse. Ten
patients responded after ﬁrst haploDLI dose, 1 patient
responded after the second haploDLI dose, and another pa-
tient responded after the third haploDLI.
Eight (26.7%) patients responded to a haploDLI dose of
1 106 CD3þ/kg, 1 patient to a 5  106 CD3þ/kg dose, while 3
patients responded to a 1107 CD3þ/kg dose. Five responders
had acute myeloid leukemia with a response rate of 31.3% in
this disease. The other 7 responders included 1 patient with
each of the following diseases: mantle cell lymphoma,
enteropathy-associated T cell lymphoma, plasmacytoid den-
driticecell neoplasm, acute lymphoblastic leukemia, myelo-
dysplastic syndrome, Hodgkin lymphoma, and T cell
prolymphocytic leukemia.
Five responders developed clinically signiﬁcant GVHD
post haploDLI (3 patients developed grade 2 to 4 aGVHD,
2 with extensive cGVHD). At end of follow-up, 8 of the 12
responders were still alive and in CR, including 5 patients
who had hematologic relapse after haploBMT. A ninth pa-
tient was still alive at end of follow-up but in relapse. Six
patients were still alive 12 months or longer after haploDLI
and in CR (96, 78, 44, 24, 18, and 18 months, respectively). Ofthose 6 patients, 2 had extensive cGVHD post haploDLI, 1 had
grade 2 aGVHD, whereas the other 3 never developed GVHD.
DISCUSSION AND CONCLUSIONS
There are limited data on the toxicity and efﬁcacy associ-
atedwith theuseofDLI for relapseafterhaploBMT[16-18]. This
is the ﬁrst report describing the toxicity and efﬁcacy of DLI
administration for relapse after haploBMT with PTCy. Twelve
(30%) patients achieved CRs after haploDLI, with a median
duration of response of 11.8 months (range, .4 to 94 months).
After amedian follow-up for the 12 responders of 17.5months
(range, 2.4 to 96months), 8were still alive in CR; 6 for a year or
longer. Consistent with the feasibility of rapid administration
of haploDLI, themedian time fromrelapse toﬁrst haploDLIwas
less than 60 days, and 28 patients received their ﬁrst haploDLI
dosewithin 90 days of relapse. Cytoreduction before haploDLI
appears to be needed to improve outcomes.
Similar to patients who receive DLI after HLA-matched
BMT, patients who received haploDLI for MRD had higher
response rates (75%) than those who received haploDLI for
overt hematologic relapse (26%). The small patient numbers
within any speciﬁc hematologic malignancy preclude mak-
ing conclusive statements about disease-speciﬁc efﬁcacy of
haploDLI. However, the response rate of 31% (5 of 16 pa-
tients) in the largest disease group, acute myeloid leukemia,
was similar to that reported for DLI given for relapse after
HLA-matched BMT [1].
Only 10 (25%) patients developed aGVHD after haploDLI
(25%), 6 of whomhad grade 3 to 4 aGVHD, but only 2 patients
with severe aGVHD (both grade 3) died. Three patients
developed cGVHD. A dose of 1 106 CD3þ/kg appears to be a
reasonable starting DLI dose in the related haploidentical
setting. This dose was associated with grade 2 to 4 GVHD in
16.7% of patients and a CR rate of 26.7% of patients within a
wide spectrum of relapsed hematologic malignancies.
The low rates of severe aGVHD that we observed after
haploDLI contrast with the high rates observed by other
groups [16,23,24]. Huang et al. reported 20 patients inwhom
granulocyte colony-stimulating factoreprimed therapeutic
haploDLIwas administered for relapsed leukemia at amedian
of 177 days after T cellereplete haploSCT [16]. The median
haploDLI dose was signiﬁcantly higher (61  106 CD3þ/kg;
range, 23 to 456  106 CD3þ/kg). The authors noted a high
incidence of aGVHD after haploDLI in the ﬁrst 9 patients
studied, prompting the use of GVHD prophylaxis after hap-
loDLI for subsequent patients. The incidence of severe aGVHD
(grade 3 to 4) after haploDLI signiﬁcantly decreased with
GVHD prophylaxis. The reported response to haploDLI was
65%, and at end of follow-up, 8 of their patients were alive in
CR at a median of 1118 days with a 2-year leukemia-free
survival of 40% [16,17]. A subsequent update from the same
group that included 168 haploDLI doses administered to 124
patients following T cellereplete haploSCT (of which 47 DLI
doses were therapeutic) conﬁrmed a higher incidence of DLI-
associated aGVHD (grade 2 to 4, 53.2%; grade 3 to 4, 28.4%),
whichwas reducedwith post-DLI GVHDprophylaxis [18].We
believe that larger haploDLI doses used by the Chinese group
accounted for their observed higher rates of aGVHD.
In our experience, haploDLI appears to be associated with
similar efﬁcacy and toxicity tomatched sibling donor alloSCT.
A haploDLI dose of 1 106 CD3þ/kg of recipient’s ideal body
weight appears to be well tolerated in most patients and
might be considered a reasonable starting haploDLI dose in
this setting. Our data indicate that haploDLI administration
for relapsed disease after haploBMT with PTCy is feasible,
Table 3
Characteristics of Patients with Hematologic Malignancies Who Responded to Haploidentical-Donor Lymphocyte Infusions (haploDLI) Given after Relapse following HLA-Haploidenticalerelated Bone Marrow Transplantation
(BMT)
Patient
No
Sex Disease BMT-to-
Relapse (d)
Type of
Relapse
Age at First
DLI (yr)
Relapse-to-
First DLI (d)
Date of
DLI
Dose of DLI
(CD3þ/kg IBW)
aGVHD Post DLI
(Overall Grade)
cGVHD
Post DLI
Duration of Response from Date of
Response Documentation, mo
Survival from Date of Last DLI (mo) and Vital
Status at End of Follow-up
1 F MDS 183 M 13 28 Dec 1,
2004
1  107 0 Extensive 94 96 (A)
2 M AML 456 H 66 49 Jul 27,
2005
5  106 0 None 3.5 4.5 (D)
3 M HL 700 H 16 84 Aug 4,
2005
1  105 0 None Proceeded to second DLI Proceeded to second DLI
Oct 27,
2005
1  106 1 None Proceeded to third DLI Proceeded to third DLI
May 31,
2006
1  107 0 Extensive 64 78 (A)
4 M AML 183 M 44 14 Mar 18,
2009
1  106 2 None 35 44 (A)
5 M T-PLL 441 H 51 56 Aug 4,
2010
1  106 0 None Proceeded to second DLI Proceeded to second DLI
Dec 16,
2010
1  107 3 None 4 12.5 (D)
6 M AML 243 H 61 204 Oct 26,
2010
1  106 0 None 22 24 (A)
7 F MCL 243 H 61 304 Apr 1,
2011
1  106 0 None 16 18 (A)
8 M EATCL 1399 H 62 28 May 12,
2011
1  106 0 None 2 17 (D)
9 M AML 167 H 70 35 May 19,
2011
1  106 0 None 16 18 (A)
10 M PDCN 973 H 39 30 Dec 9,
2011
1  106 0 None 6 12 (A*)
11 F AML 183 M 54 61 Feb 17,
2012
1  106 1 None 7.5 9.5 (A)
12 M ALL 152 H 37 106 Sep 20,
2012
1  106 4 None 0.4 2.4 (A)
MDS indicates myelodysplastic syndrome; AML, acute myeloid leukemia; HL, Hodgkin lymphoma; T-PLL, T cell prolymphocytic leukemia; MCL, mantle cell lymphoma; EATCL, enteropathy-associated T cell lymphoma; PDCN,
plasmacytoid dendritic-cell neoplasm; ALL, acute lymphoblastic leukemia; M, minimal residual disease relapse (detected by ﬂow cytometry or cytogenetics); H, hematologic relapse; IBW, ideal body weight of recipient; GVHD,
graft-versus-host-disease; aGVHD, acute graft-versus-host-disease; cGVHD, chronic graft-versus-host-disease; A, alive; D, dead; N/A, not available; C, chemotherapy; R, radiation therapy.
Data censored at December 1, 2012. All patients underwent nonmyeloablative ablative conditioning before BMT except patient no. 11, who underwent myeloablative conditioning before BMT.
* Alive in relapse.
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durable responses. Prospective evaluation is required to
conﬁrm these ﬁndings.
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